Pipeline of assets available for partnering opportunities
The SapVax platform is a versatile and powerful tool for development of a pipeline of peptide-based cancer vaccines. SapVax’s lead NY-ESO-1 targeting targeted is in late-stage preclinical development with a near-term path to the clinic. The SapVax vaccine approach is also being developed in concert with other novel immunotherapies to enhance the effectiveness of these other mechanisms. SapVax is building a broad pipeline of candidates including cancer vaccines in combination with checkpoint inhibitors, neoantigen-targeting vaccines, and combination therapies with CAR-T and other cellular therapies.